Image Place holder

Mohamed A. Kharfan-Dabaja, MD


Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Kharfan-Dabaja is intested in developing clinical trials in the field of reduced intensity conditioning stem cell transplantation for chronic lymphocytic leukemias and low grade lymphomas. He is also interested in evaluating cancer vaccines in the setting of autologous hematopoietic cell transplantation

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology

Fellowship:

  • University of Miami- Jackson Memorial Hospital - Medical Oncology- Hematology

Residency:

  • Good Samaritan Hospital of Maryland - Internal Medicine

Medical School:

  • American University of Beirut School of Medicine - MD
Participating Trials

CLINICAL TRIAL 17263
Phase I Trial of ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Tacrolimus
Open

CLINICAL TRIAL 17676
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention:
Open

CLINICAL TRIAL 17967
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; Levetiracetam; Tocilizumab; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18331
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Condition: Malignant Hematology
Intervention:
Open

CLINICAL TRIAL 18329
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18430
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: Panobinostat (LBH589)
Open

CLINICAL TRIAL 18816
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Malignant Hematology
Intervention: Atezolizumab (Tecentriq); Axicabtagene Ciloleucel (KTE-C19); KTE-C19; Not Applicable; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18374
A Phase II Trial Evaluating the use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
Condition: Malignant Hematology
Intervention: Not Applicable; Panobinostat (LBH589)
Open

CLINICAL TRIAL 18289
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19
Open

CLINICAL TRIAL 18814
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Condition: Malignant Hematology
Intervention: busulfan; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 17790
A Randomized Phase II Study of Autologous Stem Cell Transplantation with Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Marrow Infiltrating Lymphocytes (MILs); Melphalan; Tadalafil
Open

CLINICAL TRIAL 18217
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Bortezomib; FK506 (Tacrolimus); Ixazomib (Ninlaro); Melphalan; Not Applicable; PS-341 (Bortezomib); Placebo; Tacrolimus; Velcade (Bortezomib); fludarabine (Fludarabine phosphate); methotrexate
Open

CLINICAL TRIAL 18766
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); Mycophenolate Mofetil; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; busulfan; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18664
A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T cell Non-Hodgkin's Lymphoma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Carmustine; Cytarabine (Cytosine Arabinoside); FK228 (Romidepsin); Melphalan; Romidepsin; etoposide
Open

CLINICAL TRIAL 18763
A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; prednisone
Open

CLINICAL TRIAL 18783
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); FK506 (Tacrolimus); Melphalan; Pacritinib; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Tacrolimus; busulfan; fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19072
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18950
A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 18626
Carfilzomib for Treatment of Chronic Graft vs. Host Disease
Condition: Malignant Hematology
Intervention: carfilzomib (Kyprolis)
Open

CLINICAL TRIAL 19089
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)
Condition: Malignant Hematology
Intervention: Thymoglobulin; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19119
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: Jakafi (Ruxolitinib); Methylprednisolone; Ruxolitinib; prednisone
Open

CLINICAL TRIAL 18964
Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
Condition: Malignant Hematology
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Placebo
Open

CLINICAL TRIAL 19070
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19143
A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease
Condition: Malignant Hematology
Intervention: ATG; Alkeran (Melphalan); FK506 (Tacrolimus); MESNA; Melphalan; Tacrolimus; busulfan; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate
Open

CLINICAL TRIAL 19203
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); Hydroxyurea (Droxia); MESNA; Mycophenolate Mofetil; Radiotherapy; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Thiotepa (Thioplex); Thymoglobulin; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 Jan;59(1):59-68. Pubmedid: 28641468.
  • Ghanem KM, Kharfan-Dabaja MA, El-Solh H, Harris N, Kreidieh N, Nehme R, Muwakkit SA, Saab R, Bazarbachi A, Abboud MR. Fludarabine-based reduced intensity regimen for matched related donor hematopoietic stem cell transplantation in acquired severe aplastic anemia. Curr Res Transl Med. 2017 Sep;65(3):115-119. Pubmedid: 28988743.
  • Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant. 2017 Sep. Pubmedid: 28920949.
  • Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Brit J Haematol. 2017 Oct. Pubmedid: 28980314.
  • Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Tr. 2017 Oct. Pubmedid: 29032266.
  • Rafei H, Kharfan-Dabaja MA, Nishihori T. A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease. Biomedicines. 2017 Oct;5(4). Pubmedid: 29019937.
  • Massoud R, Assi R, Fares E, Haffar B, Charafeddine M, Kreidieh N, Mahfouz R, Kanj SS, El Zakhem A, Kharfan-Dabaja M, Bazarbachi A, El Cheikh J. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation. J Clin Virol. 2017 Oct;95:36-41. Pubmedid: 28843110.
  • Mina A, Sandoval Sus J, Sleiman E, Pinilla-Ibarz J, Awan FT, Kharfan-Dabaja MA. Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. Blood Rev. 2017 Oct. Pubmedid: 29122300.
  • Hill BT, Ahn KW, Hu ZH, Aljurf M, Beitinjaneh A, Cahn JY, Cerny J, Kharfan-Dabaja MA, Ganguly S, Ghosh N, Grunwald MR, Inamoto Y, Kindwall-Keller T, Nishihori T, Olsson RF, Saad A, Seftel M, Seo S, Szer J, Tallman M, Ustun C, Wiernik PH, Maziarz RT, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biol Blood Marrow Tr. 2017 Oct. Pubmedid: 29032274.
  • Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Survival. Biol Blood Marrow Tr. 2017 Oct. Pubmedid: 29079457.
  • Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2017 Oct. Pubmedid: 29126867.
  • Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):753-758. Pubmedid: 28687222. Pmcid: PMC5675815.
  • Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Ma. Biol Blood Marrow Tr. 2017 Nov;23(11):1826-1838. Pubmedid: 28797780.
  • Kharfan-Dabaja MA, El-Jurdi N, Ayala E, Kanate AS, Savani BN, Hamadani M. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?. Bone Marrow Transplant. 2017 Nov;52(11):1487-1494. Pubmedid: 28368373.
  • El Cheikh J, Massoud R, Haffar B, Fares E, Mahfouz R, Jisr T, Kharfan-Dabaja MA, Mougharbel A, Youssef A, Bazarbachi A, Ibrahim A. Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. Leuk Lymphoma. 2017 Nov;58(11):2745-2747. Pubmedid: 28351183.
  • Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socié G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica. 2017 May;102(5):958-966. Pubmedid: 28302712. Pmcid: PMC5477615.
  • Rafei H, Kharfan-Dabaja MA. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. Hematol Oncol Stem Cell Ther. 2017 May. Pubmedid: 28549767.
  • Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May;102(5):948-957. Pubmedid: 28104702. Pmcid: PMC5477614.
  • Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant. 2017 Mar;52(3):438-444. Pubmedid: 27819684.
  • Antar A, Otrock ZK, El-Cheikh J, Kharfan-Dabaja MA, Battipaglia G, Mahfouz R, Mohty M, Bazarbachi A. Inhibition of FLT3 in AML: a focus on sorafenib. Bone Marrow Transplant. 2017 Mar;52(3):344-351. Pubmedid: 27775694.
  • Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant. 2017 Mar;52(3):400-408. Pubmedid: 27941764. Pmcid: PMC5332289.
  • El-Cheikh J, El Dika I, Massoud R, Charafeddine M, Mahfouz R, Kharfan-Dabaja MA, Bazarbachi A. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):179-185. Pubmedid: 27988194.
  • El-Cheikh J, Massoud R, Fares E, Kreidieh N, Mahfouz R, Charafeddine M, Kharfan-Dabaja MA, Bazarbachi A. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. Bone Marrow Transplant. 2017 Jun;52(6):918-921. Pubmedid: 28368381.
  • Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. J Hematol Oncol. 2017 Jun;10(1):117. Pubmedid: 28606176. Pmcid: PMC5469142.
  • Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. Cancer. 2017 Jun;123(11):2035-2042. Pubmedid: 28117898. Pmcid: PMC5445018.
  • Kharfan-Dabaja MA, Aljurf M. Hematopoietic cell transplantation: Training challenges and potential opportunities through networking and integration of modern technologies to the practice setting. Hematol Oncol Stem Cell Ther. 2017 Jun. Pubmedid: 28633040.
  • Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant. 2017 Jul;52(7):1003-1009. Pubmedid: 28368376.
  • El Cheikh J, Massoud R, Abudalle I, Haffar B, Mahfouz R, Kharfan-Dabaja MA, Jisr T, Mougharbel A, Ibrahim A, Bazarbachi A. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2017 Jul;52(7):1074-1077. Pubmedid: 28394366.
  • Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Tr. 2017 Jan;23(1):60-66. Pubmedid: 27789362. Pmcid: PMC5182098.
  • Nassereddine S, Nishihori T, Padron E, Mahfouz R, Bazarbachi A, Komrokji RS, Kharfan-Dabaja MA. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):7-13. Pubmedid: 27771290.
  • Rosko A, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, Brammer J, Bredeson C, Farag S, Kharfan-Dabaja M, Lazarus HM, Marks DI, Martino Bufarull R, McGuirk J, Mohty M, Nishihori T, Nivison-Smith I, Rashidi A, Ringden O, Seftel M, Weisdorf D, Bachanova V, Saber W. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol. 2017 Jan;92(1):42-49. Pubmedid: 27712033. Pmcid: PMC5167625.
  • Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Tr. 2017 Feb;23(2):269-277. Pubmedid: 27864161. Pmcid: PMC5346183.
  • Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Brit J Haematol. 2017 Aug. Pubmedid: 28771676.
  • Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer. 2017 Aug;123(16):3141-3149. Pubmedid: 28472539. Pmcid: PMC5544566.
  • Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016 Sep;34(26):3141-3149. Pubmedid: 27269951. Pmcid: PMC5012706.
  • Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?. Bone Marrow Transplant. 2016 Sep;51(9):1256-1258. Pubmedid: 27088383.
  • Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, Kumar A. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Future Oncol. 2016 Nov;12(22):2631-2642. Pubmedid: 27381652.
  • El-Asmar J, Kharfan-Dabaja MA. Hematopoietic Cell Transplantation for Richter Syndrome. Biol Blood Marrow Tr. 2016 Nov;22(11):1938-1944. Pubmedid: 27375122.
  • El Cheikh J, Otrock ZK, Qannus AA, Kharfan-Dabaja MA, Bazarbachi A. Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):304-310. Pubmedid: 26923326.
  • El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, Kharfan-Dabaja MA. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. Biol Blood Marrow Tr. 2016 May;22(5):802-814. Pubmedid: 26713431.
  • Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA. Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy. 2016 Mar;8(4):435-447. Pubmedid: 26973125.
  • Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Pract Res Clin Haematol. 2016 Mar;29(1):54-66. Pubmedid: 27742072.
  • Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016 Mar;91(3):322-329. Pubmedid: 26701142. Pmcid: PMC4764423.
  • Salem KZ, Nishihori T, Kharfan-Dabaja MA, Horna P, Alsina M. Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. Hematol Oncol Stem Cell Ther. 2016 Mar;9(1):26-29. Pubmedid: 26169239.
  • Ayala E, LaFave D, Nishihori T, Kharfan-Dabaja MA. Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. Hematol Oncol Stem Cell Ther. 2016 Jun. Pubmedid: 27352259.
  • Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol. 2016 Jun;34(16):1864-1871. Pubmedid: 27044940. Pmcid: PMC4966345.
  • El-Asmar J, Kharfan-Dabaja MA, Ayala E. Acute pericarditis and tamponade from Coxsackie B3 in an adult Hematopoietic-Cell-Allograft recipient: A rare but potentially serious complication. Hematol Oncol Stem Cell Ther. 2016 Jun;9(2):82-85. Pubmedid: 26183671.
  • Antar AI, Otrock ZK, Kharfan-Dabaja MA, Mahfouz RA, Alameddine RS, El-Majzoub NM, Salem ZM. Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab. Indian J Hematol Blood Transfus. 2016 Jun;32(Suppl 1):219-222. Pubmedid: 27408396. Pmcid: PMC4925473.
  • Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Brit J Haematol. 2016 Jul;174(2):235-248. Pubmedid: 26989808. Pmcid: PMC4940282.
  • Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant. 2016 Jan;51(1):58-66. Pubmedid: 26437062. Pmcid: PMC4703480.
  • Kharfan-Dabaja MA, Nishihori T, Bazarbachi A. Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia. Lancet Oncol. 2016 Jan;17(1):e1. Pubmedid: 26758754.
  • Bazarbachi A, Labopin M, Kharfan-Dabaja MA, Schwerdtfeger R, Volin L, Bourhis JH, Socié G, Daguindau E, Gedde-Dahl T, Rambaldi A, Karas M, Schlimok G, Blaise D, Chevallier P, Malard F, Schmid C, Esteve J, Nagler A, Mohty M. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. Haematologica. 2016 Jan;101(1):e34-e37. Pubmedid: 26405153. Pmcid: PMC4697906.
  • Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016 Feb;127(7):938-947. Pubmedid: 26670632. Pmcid: PMC4760094.
  • El-Asmar J, Gonzalez R, Bookout R, Mishra A, Kharfan-Dabaja MA. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. Hematol Oncol Stem Cell Ther. 2016 Dec;9(4):157-161. Pubmedid: 26684920.
  • Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2016 Dec;22(12):2201-2207. Pubmedid: 27660169.
  • Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro J, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Tr. 2016 Dec;22(12):2117-2125. Pubmedid: 27660167. Pmcid: PMC5116249.
  • El Fakih R, Kharfan-Dabaja MA, Aljurf M. Refining the Role of Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia as Novel Therapies Emerge. Biol Blood Marrow Tr. 2016 Dec;22(12):2126-2133. Pubmedid: 27375123.
  • Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug;47:78-83. Pubmedid: 27285853.
  • Kharfan-Dabaja MA. Hope for BET inhibition in patients with leukaemia or lymphoma. Lancet Haematol. 2016 Apr;3(4):e157-e158. Pubmedid: 27063970.
  • Kharfan-Dabaja MA. Guadecitabine for AML and MDS: hype or hope?. Lancet Oncol. 2015 Sep;16(9):1009-1011. Pubmedid: 26296955.
  • Hassoun Y, Kharfan-Dabaja MA, Baz R. Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response. Hematol Oncol Stem Cell Ther. 2015 Sep;8(3):138-139. Pubmedid: 25732670.
  • Nishihori T, El-Asmar J, Shah B, Hussaini M, Komrokji R, List A, Anasetti C, Kharfan-Dabaja MA. Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature. Bone Marrow Transplant. 2015 Oct;50(10):1388-1392. Pubmedid: 26191951.
  • Inamoto Y, Flowers ME, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdén OT, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ. Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biol Blood Marrow Tr. 2015 Oct;21(10):1776-1782. Pubmedid: 26033280. Pmcid: PMC4568149.
  • Nishihori T, Shaheen M, El-Asmar J, Aljurf M, Kharfan-Dabaja MA. Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. Immunotherapy. 2015 Oct;7(10):1059-1071. Pubmedid: 26507225.
  • Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015 Nov;50(11):1416-1423. Pubmedid: 26237164. Pmcid: PMC4633349.
  • Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplant. 2015 Nov;50(11):1487-1489. Pubmedid: 26301969. Pmcid: PMC4863975.
  • Antar A, Kharfan-Dabaja MA, Mahfouz R, Bazarbachi A. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. Pubmedid: 25550214.
  • Kharfan-Dabaja MA, Nishihori T. Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. Expert Rev Vaccines. 2015 Mar;14(3):341-350. Pubmedid: 25468066.
  • Ayala E, Figueroa J, Perkins J, Kim J, Yue B, Riches M, Nishihori T, Locke F, Anasetti C, Kharfan-Dabaja MA. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):335-340. Pubmedid: 25659459.
  • Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Tr. 2015 Jun;21(6):1074-1082. Pubmedid: 25805300.
  • Chavez JC, Dalia S, Sandoval-Sus J, Kharfan-Dabaja MA, Al-Ali N, Komrokji R, Padron E, Corrales-Yepez G, Rock-Klotz J, Pinilla-Ibarz J. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S14-S18. Pubmedid: 26297266.
  • Antar A, Otrock ZK, Kharfan-Dabaja MA, Ghaddara HA, Kreidieh N, Mahfouz R, Bazarbachi A. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis. Bone Marrow Transplant. 2015 Jun;50(6):813-817. Pubmedid: 25751646.
  • Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica. 2015 Jul;100(7):970-977. Pubmedid: 25840599. Pmcid: PMC4486232.
  • Kharfan-Dabaja MA. Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations. Immunotherapy. 2015 Jan;7(1):47-56. Pubmedid: 25572479.
  • Otrock ZK, Chamseddine N, Salem ZM, Wehbe T, Al-Ayoubi M, Dhaini M, Kattan J, Mokaddem W, Nasr TA, Jradi O, Farhat FS, Wehbe M, Haidar MH, Kharfan-Dabaja MA, Bitar N, Hajj ME, Kadri AM, Kamar FG, Yassine H, Khodr H, Taher AT, Hakime N, Mahfouz RA, Serhal W, Bazarbachi A, Farhat HZ. A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. Am J Blood Res. 2015 Dec;5(2):86-90. Pubmedid: 27069756. Pmcid: PMC4769350.
  • Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Tr. 2015 Dec;21(12):2091-2099. Pubmedid: 26253007. Pmcid: PMC4639453.
  • Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Dec;50(12):1513-1518. Pubmedid: 26301967. Pmcid: PMC4548821.
  • Reljic T, Kumar A, Djulbegovic B, Kharfan-Dabaja MA. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. Bone Marrow Transplant. 2015 Aug;50(8):1144. Pubmedid: 26242579.
  • Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Hamladji RM, Blaise D, Socié G, Lioure B, Bermudez A, Lopez-Corral L, Or R, Arcese W, Fegueux N, Nagler A, Mohty M. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2014 Sep;49(9):1170-1175. Pubmedid: 24978140.
  • Ayala E, Chalhoub J, Kharfan-Dabaja MA. Umbilical cord blood transplantation induces a durable remission in hepatosplenic gamma-delta T cell lymphoma with associated hemophagocytic lymphohistiocytosis. Am J Hematol. 2014 Sep;89(9):934-935. Pubmedid: 24861697.
  • Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leuk Res. 2014 Oct;38(10):1165-1172. Pubmedid: 24889511. Pmcid: PMC4625795.
  • Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, Kumar A, Kharfan-Dabaja MA. Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. Biol Blood Marrow Tr. 2014 Nov;20(11):1677-1686. Pubmedid: 24867779.
  • Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone Marrow Transplant. 2014 May;49(5):599-606. Pubmedid: 24442246.
  • Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol. 2014 Mar;21(2):123-130. Pubmedid: 24335709. Pmcid: PMC4124617.
  • Kharfan-Dabaja MA, Wierda WG, Cooper LJ. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia. 2014 Mar;28(3):507-517. Pubmedid: 24157582.
  • Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol Blood Marrow Tr. 2014 Jun;20(6):776-780. Pubmedid: 24534108.
  • Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2014 Jul;(7):CD010280. Pubmedid: 25061777.
  • McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Tr. 2014 Jul;20(7):960-968. Pubmedid: 24641829. Pmcid: PMC4057955.
  • Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant. 2014 Jan;49(1):11-16. Pubmedid: 23995098.
  • Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol. 2014 Jan;51(1):73-86. Pubmedid: 24468319.
  • Nishihori T, Hassoun Y, Zhang L, Shain K, Alsina M, Kharfan-Dabaja MA. High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation. Bone Marrow Transplant. 2014 Jan;49(1):148-149. Pubmedid: 23933759.
  • Kharfan-Dabaja MA. A new dawn for gemtuzumab ozogamicin?. Lancet Oncol. 2014 Aug;15(9):913-914. Pubmedid: 25008259.
  • Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M. Monoclonal Antibodies in Conditioning Regimens for Hematopoietic Cell Transplantation. Biol Blood Marrow Tran. 2013 Apr;19(9):1288-1300. Pubmedid: 23618718.
  • Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA. Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy. 2013 Sep;5(9):1005-1020. Pubmedid: 23998734. Pmcid: PMC4905571.
  • Otrock ZK, Saab J, Aftimos G, Nasr F, Farhat FS, Khairallah S, Abadjian G, Ghosn M, Sidani H, Ibrahim A, Tawil A, Ghorra C, Meguerian Z, Mokaddem W, Dayeh W, Salem Z, Chahine G, Bitar N, Mugharbel A, Makdessi J, Khater C, El Hajj M, Abi Gerges D, Sfeir C, Kattan J, Ibrahim K, Saade M, Sadek H, Mahfouz RA, Kharfan-Dabaja MA, Zaatari G, Bazarbachi A. A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses. Pathol Oncol Res. 2013 Oct;19(4):715-722. Pubmedid: 23653112.
  • Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?. Bone Marrow Transplant. 2013 Nov;48(12):1489-1496. Pubmedid: 23584438.
  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Brit J Haematol. 2013 Nov;163(3):315-325. Pubmedid: 24033280.
  • El-Majzoub N, Kharfan-Dabaja MA, Boulos FI, Mahfouz R, Eloubeidi MA. Diagnosing diffuse large B-cell non-hodgkin lymphoma by endoscopic ultrasound-fine-needle aspiration of a splenic mass. J Clin Oncol. 2013 May;31(13):e223-e225. Pubmedid: 23530099.
  • El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B, Kharfan-Dabaja MA. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy. 2013 May;5(5):457-466. Pubmedid: 23638742.
  • Baydoun M, Otrock ZK, Okaily S, Nehme R, Abu-Chahine R, Hamdan A, Noureddine S, Kanj S, Kanafani Z, Bazarbachi A, Kharfan-Dabaja MA. Prophylactic administration of doxycycline reduces central venous catheter infections in patients undergoing hematopoietic cell transplantation. Mediterr J Hematol Infect Dis. 2013 Mar;5(1):e2013015. Pubmedid: 23505603. Pmcid: PMC3591294.
  • Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Jul;88(7):566-570. Pubmedid: 23605934. Pmcid: PMC4685468.
  • Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Tr. 2013 Jul;19(7):1087-1093. Pubmedid: 23632090. Pmcid: PMC4667782.
  • Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013 Jul;122(4):499-506. Pubmedid: 23692856. Pmcid: PMC3724189.
  • Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Tr. 2013 Jul;19(7):1006-1012. Pubmedid: 23396213.
  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2013 Jan;6:2. Pubmedid: 23289975. Pmcid: PMC3548722.
  • Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Smith LR, Rolland AP, Kenney RT. Reanalysis of TransVax immunogenicity. Lancet Infect Dis. 2013 Jan;13(1):18. Pubmedid: 23257230.
  • Bazarbachi A, Labopin M, Ghavamzadeh A, Giebel S, Al-Zahrani H, Ladeb S, Leone G, Abdel-Rahman F, Liso V, Hamidieh AA, Rasheed W, Ibrahim A, Alabdulaaly A, Kyrcz-Krzemien S, Arnold R, Kharfan-Dabaja MA, Alimoghaddam K, Aljurf M, Mohty M. Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers. Bone Marrow Transplant. 2013 Jan;48(8):1065-1069. Pubmedid: 23353802.
  • Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau JL, Kharfan-Dabaja MA. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Feb;19(8):1144-1151. Pubmedid: 23416092.
  • Kharfan-Dabaja MA, Pidala J, Kumar A, Terasawa T, Djulbegovic B. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant. 2012 Sep;47(9):1164-1170. Pubmedid: 22562081.
  • Kharfan-Dabaja MA, Otrock ZK, Bacigalupo A, Mahfouz RA, Geara F, Bazarbachi A. A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita. Bone Marrow Transplant. 2012 Sep;47(9):1254-1255. Pubmedid: 22246089.
  • Kanate AS, Kharfan-Dabaja MA, Hamadani M. Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma. Bone Marrow Res. 2012 Oct;2012:897215. Pubmedid: 23097707. Pmcid: PMC3477524.
  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.
  • Zibara K, Hamdan R, Dib L, Sindet-Pedersen S, Kharfan-Dabaja M, Bazarbachi A, El-Sabban M. Acellular bone marrow extracts significantly enhance engraftment levels of human hematopoietic stem cells in mouse xeno-transplantation models. PLoS One. 2012 Nov;7(7):e40140. Pubmedid: 22768336. Pmcid: PMC3388059.
  • Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May;118(10):2659-2664. Pubmedid: 21956402.
  • Sibai H, Ishak RS, Halawi R, Otrock ZK, Salman S, Abu-Alfa A, Kharfan-Dabaja MA. Non-uremic calcific arteriolopathy (calciphylaxis) in relapsed/refractory Hodgkin's lymphoma: a previously unreported association. J Clin Oncol. 2012 Mar;30(7):e88-e90. Pubmedid: 22231039.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2012 Jul;18(7):1099-1107. Pubmedid: 22198540.
  • Kharfan-Dabaja MA, Bazarbachi A. Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Cancer Control. 2012 Jan;19(1):68-75. Pubmedid: 22143063.
  • Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec;97(12):1882-1889. Pubmedid: 22689677. Pmcid: PMC3590095.
  • Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, Mohty M, Djulbegovic B. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012 Apr;26(4):582-588. Pubmedid: 22182922.
  • Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012 Apr;12(4):290-299. Pubmedid: 22237175.
  • Ang C, O'Reilly EM, Abou-Alfa GK, Shamseddine A, Skouri H, Tawil A, Eloubeidi MA, Lowery M, Kharfan-Dabaja M, Kaprealian T, Temraz S, Sibai H, Farran H, Shah MA. Gastrointestinal cancer educational case series: management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor. J Gastrointest Cancer. 2011 Sep;42(3):165-170. Pubmedid: 21128012.
  • Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, Perkins J, Raychaudhuri J, Fernandez H, Anasetti C. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Tr. 2011 Oct;17(10):1505-1511. Pubmedid: 21385623.
  • Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2011 Oct;(10):CD008818. Pubmedid: 21975786.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner JA, Miller S, Anasetti C. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone Marrow Transplant. 2011 Nov;46(11):1418-1425. Pubmedid: 21132026.
  • Kharfan-Dabaja MA, Cutler CS. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol. 2011 May;93(5):578-585. Pubmedid: 21547615.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, Fernandez H. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant. 2011 May;46(5):641-649. Pubmedid: 20711242.
  • Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar;35(3):301-304. Pubmedid: 21109304.
  • Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Tr. 2011 Mar;17(3):384-393. Pubmedid: 20655389.
  • Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-260. Pubmedid: 21658652.
  • Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun;35(6):e81-e83. Pubmedid: 21232795.
  • Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez H, Anasetti C. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Tr. 2011 Feb;17(2):239-248. Pubmedid: 20637884.
  • Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol. 2011 Feb;93(2):206-212. Pubmedid: 21246311.
  • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.
  • Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-511. Pubmedid: 21813352.
  • Nishihori T, Kharfan-Dabaja MA, Ochoa-Bayona JL, Bazarbachi A, Pasquini M, Alsina M. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2011 Apr;4(1):1-9. Pubmedid: 21460601.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2010 Oct;3:36. Pubmedid: 20925957. Pmcid: PMC2958877.
  • Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Bookout R, Anasetti C, Kharfan-Dabaja MA. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant. 2010 Oct;15(4):21-29. Pubmedid: 21183872.
  • Kharfan-Dabaja MA, Bazarbachi A. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2010 Oct;16(10):1347-1354. Pubmedid: 20083213.
  • Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. Am J Hematol. 2010 Nov;85(11):904-907. Pubmedid: 20890908.
  • Kharfan-Dabaja MA, Pidala J, Anasetti C. Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting. Blood. 2010 May;115(21):4316-4317. Pubmedid: 20508174.
  • Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, Anasetti C. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant. 2010 May;45(5):919-924. Pubmedid: 19767783.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Tr. 2010 Jul;16(7):937-947. Pubmedid: 20102746.
  • Kharfan-Dabaja MA, Velez A, Richards K, Greene JN, Field T, Sandin R. Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int J Hematol. 2010 Jan;91(1):124-127. Pubmedid: 20013322.
  • Mourad AR, Kharfan-Dabaja MA, Benson K, Moscinski LC, Baz RC. Leptomeningeal myeloma as the sole manifestation of relapse: an unusual presentation. Am J Med Sci. 2010 Jan;339(1):81-82. Pubmedid: 19875952.
  • Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb;45(2):255-260. Pubmedid: 19543327.
  • Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010 Aug;45(8):1347-1351. Pubmedid: 19966849.
  • Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010 Apr;45(4):662-667. Pubmedid: 19684623. Pmcid: PMC2850960.
  • Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Tr. 2009 Sep;15(9):1005-1013. Pubmedid: 19660713.
  • Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Tr. 2009 Sep;15(9):1116-1121. Pubmedid: 19660725.
  • Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2009 Nov;15(11):1415-1421. Pubmedid: 19822301.
  • Matos-Fernandez NA, Abou Mourad YR, Caceres W, Kharfan-Dabaja MA. Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Tran. 2009 Jun;15(6):656-661. Pubmedid: 19450749.
  • Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009 Jan;101(2):100-106. Pubmedid: 19141779.
  • Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant. 2009 Aug;15(8):893-902. Pubmedid: 19589478.
  • Fernandez HF, Kharfan-Dabaja MA. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities. Cancer Control. 2009 Apr;16(2):153-157. Pubmedid: 19337201.
  • Kharfan-Dabaja M, Chavez J, Khorfan K, Pinilla-Ibarz J. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer. 2008 Sep;113(5):897-906. Pubmedid: 18618518.
  • Abou Mourad YR, Fernandez HF, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Biol Blood Marrow Tr. 2008 Sep;14(9):949-958. Pubmedid: 18721758.
  • Raychaudhuri J, Cualing H, Haider K, Kharfan-Dabaja M. Granulocytic sarcoma and chronic lymphocytic leukemia of the gastrointestinaltract after allogeneic hematopoietic cell transplantation mimickinggraft-versus-host disease. Leuk Lymphoma. 2008 Feb;49(2):350-352. Pubmedid: 18231925.
  • Kharfan-Dabaja M, Abou Mourad Y, Fernandez H, Pasquini M, Santos E. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant. 2007 Sep;13(9):997-1004. Pubmedid: 17697961.
  • Kharfan-Dabaja M, Kumar A, Behera M, Djulbegovic B. Systematic review of high dose chemotherapy and autologous haematopoietic stemcell transplantation for chronic lymphocytic leukaemia: what is the publishedevidence. Br J Haematol. 2007 Oct;139(2):234-242. Pubmedid: 17897299.
  • Kharfan-Dabaja M, Fahed R, Hussein M, Santos E. Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Expert Opin Inv Drug. 2007 Nov;16(11):1799-1815. Pubmedid: 17970639.
  • Kharfan-Dabaja MA, Anasetti C, Ferrara JL. Sympathectomy protects denervated skin from graft-versus-host disease. Biol Blood Marrow Transplant. 2007 Mar;13(3):369-370. Pubmedid: 17317591.
  • Kharfan-Dabaja M, Ayala E, Greene J, Rojiani A, Murtagh F, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Jan;39(2): 101-7. Pubmedid: 17143300.
  • Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh F, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Feb;39(4):253-254. Pubmedid: 17290282.
  • Kharfan-Dabaja M, Anasetti C, Santos E. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol Blood Marrow Transplant. 2007 Apr;13(4):373-385. Pubmedid: 17382245.
  • Santos E, Kharfan-Dabaja M. New horizons in multiple myeloma therapy. Expert Rev Anticancer Ther. 2006 Oct;6(10):1483-1501. Pubmedid: 17069532.
  • Kamble R, Selby G, Mims M, Kharfan-Dabaja M, Ozer H, George J. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Tr. 2006 May;12(5):506-510. Pubmedid: 16635785.
  • Dunn T, Allen R, Bates F, Kurkjian C, Kamble R, Kharfan-Dabaja M. Cytogenetic changes associated with myelodysplastic syndrome affecting bone marrow engraftment analysis. J Mol Diagn. 2006 May;8(2):288-294. Pubmedid: 16645218. Pmcid: PMC1867594.
  • Kurkjian C, Patel S, Kamble R, Dunn S, Kern W, Kharfan-Dabaja M. Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet. 2006 Mar;165(2):176-179. Pubmedid: 16527614.
  • Santos E, Kharfan-Dabaja M, Ayala E, Raez L. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Dec;47(12):2453-2476. Pubmedid: 17169792.
  • Kharfan-Dabaja M, Patel S, Osunkoya A, Kojouri K, Kamble R, Yang J, HashmiM, Ozer H, Selby G. Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining. Clin Lab Haematol. 2006 Aug;28(4):254-258. Pubmedid: 16898965.
  • Hamadani M, Kharfan-Dabaja M, Kamble R, Kern W, Ozer H. Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature. J Okla State Med Assoc. 2006 Apr;99(4):154-156. Pubmedid: 16703935.
  • Armor J, Fazili J, Toubia N, Kern W, Kamble R, Kharfan-Dabaja M. Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. Am J Hematol. 2005 Mar;78(3):212-215. Pubmedid: 15726605.
  • Kamble R, Pant S, Selby G, Kharfan-Dabaja M, Sethi S, Kratochvil K, KohrtN, Ozer H. Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts. Transfusion. 2005 Jun;45(6):874-878. Pubmedid: 15934984.
  • Kurkjian C, Armor JF, Kamble R, Ozer H, Kharfan-Dabaja MA. Symptomatic metastases to the pituitary infundibulum resulting from primary breast cancer. Int J Clin Oncol. 2005 Jun;10(3):191-194. Pubmedid: 15990968.
  • Kharfan-Dabaja M, Ayala E, Lindner I, Cejas P, Bahlis N, Kolonias D, CarlsonLM, Lee K. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol Immunother. 2005 Jan;54(1):25-36. Pubmedid: 15693136.
  • Li Q, Ozer H, Lindner I, Lee K, Kharfan-Dabaja M. Protein kinase C blockade inhibits differentiation of myeloid blasts into dendritic cells by calcium ionophore A23187. Int J Hematol. 2005 Feb;81(2):131-137. Pubmedid: 15765781.
  • Ayala E, Kharfan-Dabaja M. Protective conditioning for acute graft-versus-host disease. New England J Med. 2005 Dec;353(25):2718-2718. Pubmedid: 16371641.
  • Ayala E, Rosado MF, Morgensztern D, Kharfan-Dabaja MA, Byrnes JJ. Heparin-induced thrombocytopenia presenting with thrombosis of multiple saphenous vein grafts and myocardial infarction. Am J Hematol. 2004 Aug;76(4):383-385. Pubmedid: 15282674.
  • Khan M, Hussein K, Walter M, Hasan M, Kern W, Kharfan-Dabaja M. Granulocytic sarcoma presenting with malignant anasarca in a patient with secondary acute myeloid leukemia. Int J Hematol. 2004 Apr;79(3):250-252. Pubmedid: 15168593.
  • Santos ES, Raez LE, Kharfan-Dabaja MA, Angulo J, Restrepo A, Byrnes JJ. Survival of renal allograft following de novo hemolytic uremic syndrome after kidney transplantation. Transplant P. 2003 Jun;35(4):1370-1374. Pubmedid: 12826162.
  • Kharfan-Dabaja M, Morgensztern D, Santos E, Goodman M, Fernandez H. Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant. Bone Marrow Transplant. 2003 Jan;31(2):129-131. Pubmedid: 12621495.
  • Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. J Immunol. 2003 Aug;171(4):1780-1791. Pubmedid: 12902478.
  • Couriel DR, Beguelin GZ, Giralt S, De Lima M, Hosing C, Kharfan-Dabaja MA, Anagnostopoulos A, Champlin R. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant. 2002 Oct;30(8):543-546. Pubmedid: 12379897.
  • Bahlis N, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez H, Boise L, Lee K. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2002 Dec;8(12):3658-3668. Pubmedid: 12473574.
  • Morgensztern D, Kharfan-Dabaja M, Tsai H, Lian E. Warm-antibody autoimmune hemolytic anemia developing after thrombotic thrombocytopenic purpura. Acta Haematol. 2002;108(3):154-156. Pubmedid: 12373088.
  • Kharfan Dabaja MA, Morgensztern D, Markoe AM, Bartlett-Pandite L. Radiation recall dermatitis induced by methotrexate in a patient with Hodgkin's disease. Am J Clin Oncol. 2000 Oct;23(5):531-533. Pubmedid: 11039518.